Nearly one in ten British people either used or were interested in using strong prescription weight-loss drugs in early 2025. These results showed that the country is quietly facing a growing public health problem. 

The size of the demand is explained in more detail in a new nationally representative household survey published in BMC Medicine. The study asked 5,260 adults between January and March 2025 to fill out the survey. Researchers say that between 4.9 million and 5 million people have used or intended to use GLP-1 or GLP-1/GIP receptor agonists to lose weight in the last few months.

Liraglutide, semaglutide, and tirzepatide are some of these drugs. They function by replicating proteins in the body that control hunger and blood sugar levels.In simple terms, they help the body control sugar levels and make people feel full faster and for longer. They were first made to treat diabetes, but now they are widely advertised as very successful ways to lose weight. 

Access, on the other hand, says something different. In the UK, these drugs are approved to help people lose weight, but only about 220,000 people will be able to get NHS care between 2025 and 2028. At the heart of the problem is this big difference between what people want and what is available. 

The study found that 2.9% of people had used one of these weight loss drugs in the past year, and 6.5% said they planned to use them in the next year. This means that, on a national level, 1.6 million people may have already used the drugs, and another 3.3 million have said they are interested. 

Safety is especially important. 15% of recent users said they took weight loss drugs that aren't legal in the UK. The authors think the spike might be because of recommending drugs that aren't on the label or people getting drugs from places other than doctors, like online sellers, where there aren't any clinical checks or follow-ups. 

Women, those between the ages of 45 and 55, and people who had moderate to severe psychological distress in the past month were more likely to use and show interest in it. People who had money troubles or health problems for a long time were also more interested. 

The authors add, "These results show that there is a lot of unmet need." They also say that the huge amount of publicity around these substances could be making vulnerable groups use them in ways that are dangerous or out of control. 

If the study shows anything, it's not that medicine has gotten better. Instead, it shows how mental illness, poverty, and desperation affect health decisions. The researchers say that the NHS should keep an eye on how much it is being used, how it affects health, and how stressed the system is in general. They forcefully argue how important it is to give these drugs in a way that is fair, safe, and lasts a long time.

If demand keeps going up, it's clear what lawmakers need to do: they need to keep a tight grip on it. There was hope that a medicine would help, but if they don't, it could turn into another quiet public health problem.